Italy Clinical Oncology Next Generation Sequencing Market Size & Outlook

The clinical oncology next generation sequencing market in Italy is expected to reach a projected revenue of US$ 61.1 million by 2033. A compound annual growth rate of 16.8% is expected of Italy clinical oncology next generation sequencing market from 2025 to 2033.
Revenue, 2024 (US$M)
$15.2
Forecast, 2033 (US$M)
$61.1
CAGR, 2025 - 2033
16.8%
Report Coverage
Italy

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Italy clinical oncology next generation sequencing market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

Related Markets

Italy clinical oncology next generation sequencing market highlights

  • The Italy clinical oncology next generation sequencing market generated a revenue of USD 15.2 million in 2024 and is expected to reach USD 61.1 million by 2033.
  • The Italy market is expected to grow at a CAGR of 16.8% from 2025 to 2033.
  • In terms of segment, targeted sequencing and resequencing was the largest revenue generating technology in 2024.
  • Whole Genome Sequencing is the most lucrative technology segment registering the fastest growth during the forecast period.


Clinical oncology next generation sequencing market data book summary

Market revenue in 2024USD 15.2 million
Market revenue in 2033USD 61.1 million
Growth rate16.8% (CAGR from 2025 to 2033)
Largest segmentTargeted sequencing and resequencing
Fastest growing segmentWhole Genome Sequencing
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationWhole Exome Sequencing, Targeted Sequencing and Resequencing, Whole Genome Sequencing
Key market players worldwideIllumina Inc, Thermo Fisher Scientific Inc, Roche, Agilent Technologies Inc, Myriad Genetics Inc, PerkinElmer, Roche Holding AG, Pacific Biosciences of California Inc, Oxford Nanopore Technologies PLC, Paradigm Healthcare, Eurofins Scientific SE, Qiagen NV


Other key industry trends

  • In terms of revenue, Italy accounted for 3.2% of the global clinical oncology next generation sequencing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Europe, Germany clinical oncology next generation sequencing market is projected to lead the regional market in terms of revenue in 2033.
  • UK is the fastest growing regional market in Europe and is projected to reach USD 131.0 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Clinical Oncology Next Generation Sequencing Market Companies

Name Profile # Employees HQ Website
Oxford Nanopore Technologies PLC View profile 1133 Edmund Halley Road, Gosling Building, Oxford Science Park, Oxford, Oxfordshire, United Kingdom, OX4 4DQ https://www.nanoporetech.com
Pacific Biosciences of California Inc View profile 796 1305 O’Brien Drive, Menlo Park, CA, United States, 94025 https://www.pacb.com
PerkinElmer View profile 10001+ Waltham, Massachusetts, United States, North America http://www.perkinelmer.com
Roche View profile 10001+ Basel, Basel-Stadt, Switzerland, Europe http://www.roche.com
Paradigm Healthcare View profile 11-50 San Francisco, California, United States, North America https://paradigm-healthcare.com
Myriad Genetics Inc View profile 2700 320 Wakara Way, Salt Lake City, UT, United States, 84108 https://www.myriad.com
Eurofins Scientific SE View profile 61798 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 https://www.eurofins.com
Qiagen NV View profile 5900 Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL https://www.qiagen.com
Agilent Technologies Inc View profile 17700 5301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051 https://www.agilent.com
Illumina Inc View profile 9300 5200 Illumina Way, San Diego, CA, United States, 92122 https://www.illumina.com
Roche Holding AG View profile 103605 Grenzacherstrasse 124, Basel, Switzerland, 4070 https://www.roche.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com

Italy clinical oncology next generation sequencing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to clinical oncology next generation sequencing market will help companies and investors design strategic landscapes.


Targeted sequencing and resequencing was the largest segment with a revenue share of 75% in 2024. Horizon Databook has segmented the Italy clinical oncology next generation sequencing market based on whole exome sequencing, targeted sequencing and resequencing, whole genome sequencing covering the revenue growth of each sub-segment from 2021 to 2033.


Reasons to subscribe to Italy clinical oncology next generation sequencing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Italy clinical oncology next generation sequencing market databook

  • Our clientele includes a mix of clinical oncology next generation sequencing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Italy clinical oncology next generation sequencing market, including forecasts for subscribers. This country databook contains high-level insights into Italy clinical oncology next generation sequencing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Italy clinical oncology next generation sequencing ngs market size, by technology, 2021-2033 (US$M)

Italy Clinical Oncology Next Generation Sequencing Market Share, 2024 & 2033 (US$M)

Italy clinical oncology next generation sequencing ngs market size, by technology, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online